Amarantus Bioscience Holdings Inc (AMBS)

[JPetroInc]

How did this agreement get reached with these fatal terms & conditions - and with a notorious 'off-shore' hedge fund no less

just who at AMBS endorsed this:

http://ir.amarantus.com/all-sec-filings/content/0001144204-15-025377/v408542_8k.htm

"The Series G Preferred Stock may be converted into shares of common stock at any time at the option of the holder."

"If the Company elects to pay the conversion premium amount in the form of common stock the number of shares to be issued shall be calculated by using 80% of the average of the lowest 5 individual daily volume weighted average prices during the measuring period, not to exceed 100% of the lowest sales prices on the last day of such period, less $0.005 per share of common stock.. Following an Event of Default, the number of shares to be issued shall be calculated by using 65% of the average of the lowest 5 individual daily volume weighted average prices during the measuring, less $0.005 per share of common stock not to exceed 70% of the lowest sales prices on the last day of such period less $0.005 per share."

https://twitter.com/discoverfund

How did Jeffrey Fessler and Marcelle Balcombe of Sichenzia Ross Friedman Ference, LLP, who were retained to help AMBS up-listing to the NASDAQ, get involved with putting together a toxic death spiral floorless deal with slim bucket Discover Growth Fund? Was there a 'back door' to this deal that we don't know about.

http://srff.com/?s=amarantus&lang=en

Just who is this guy???



http://srff.com/jeffrey-fessler/

Jeffrey J. Fessler joined Sichenzia Ross Friedman Ference LLP in 2004. Mr. Fessler is principally engaged in the practice of corporate and securities law. His practice is focused on the representation of public and private companies, principally in the biotechnology industry. Mr. Fessler has extensive experience representing investment banks and companies in public offerings and private placements as well as exchange listings and compliance. In addition, Mr. Fessler has been involved in a wide variety of corporate transactions, including mergers and acquisitions, joint ventures, proxy contests, restructurings and private equity and debt financings. In addition to the biotechnology industry, Mr. Fessler also represents companies in a variety of industries, including technology, telecommunications, broadcasting and healthcare.

Prior to joining Sichenzia Ross Friedman Ference LLP, Mr. Fessler practiced corporate and securities law at several large firms, including Akin, Gump, Strauss, Hauer & Feld and Orrick, Herrington & Sutcliffe.

Recent Representative Transactions

-Represented Synergy Pharmaceuticals, Inc. in a $200 million Convertible Note Rule 144A Offering

-Represented Synergy Pharmaceuticals Inc. in its $17.25 million public offering and uplisting to Nasdaq as well as a subsequent $51 million public offering.

-Represented Trovagene, Inc. in its $9.2 million public offering and uplisting to Nasdaq.

-Represented Northwest Biopharmaceuticals, Inc. in its $12 Million Public Offerings and Uplisting to Nasdaq

-Represented Sorrento Therapeutics, Inc. in its $34.6 Million Public Offering and Uplisting to Nasdaq as well as a subsequent $28.8 million Public Offering

-Represented an underwriter in a $10.4 million public offering and Nasdaq uplisting for a cancer drug development company.

Awards & Recognition

-Awarded 2014 SmartCEO Attorney of the Year

Memberships

Mr. Fessler is a Certified Public Accountant (New Jersey)